Why Moderna Stock Plunged 18% Despite Positive Cancer Vaccine Data: Key Takeaways

 

Moderna closed at $202.63 in US trading on October 22, down $43.18 or 17.57%, erasing roughly $24 billion of market value. The stock traded as low as $180.80 intraday, and Yahoo Finance reported it down 25.2% at $183.88 at one point during the session. Volume ran roughly 49.3 million to 49.9 million shares against a three-month average near 20 million, and trading was briefly halted during the day.

 

On the same day, Merck and Moderna formally announced results from the Phase 3 INTerpath-001 trial: the individualised neoantigen therapy intismeran autogene combined with KEYTRUDA met the primary endpoint of recurrence-free survival and the key secondary endpoint of distant metastasis-free survival in patients with completely resected stage IIB to IV melanoma, with statistically significant and clinically meaningful improvements over KEYTRUDA alone. Per figures reported in the press, the combination reduced the risk of recurrence or death by 42% and the risk of distant metastasis or death by 38%, while overall survival data are not yet mature.

 

Two common misreadings need clearing first. This was not a failed trial, since the company states the study met its primary endpoint and a key secondary endpoint with a safety profile consistent with prior studies of the combination and no new safety signals. And a 42% risk reduction is not a 42% cure rate, since it describes how far the risk of experiencing recurrence or death fell relative to the control arm over the observation period rather than the proportion of patients cured.

 

What actually needs explaining is something else: why positive results produced a sharp decline. The answer lies not in the data but in the gap between the data and prior expectations, together with how far the stock had already risen.

 

 

 

The decline and its measures. The stock closed at $202.63 on October 22, down 17.57%, erasing roughly $24 billion of market value, with an intraday low of $180.80 and a decline of as much as 25.2% during the session.

 

The trial met its endpoints. Phase 3 INTerpath-001 met the primary endpoint of recurrence-free survival and the key secondary endpoint of distant metastasis-free survival at a pre-specified interim analysis, with no new safety signals.

 

What 42% actually means. The combination reduced the risk of recurrence or death by 42% relative to KEYTRUDA alone, which is neither a cure rate nor an absolute share of patients.

 

A higher benchmark existed. Five-year Phase 2b KEYNOTE-942 data showed a 49% reduction in recurrence-free survival risk and a 59% reduction in distant metastasis-free survival risk, both above the Phase 3 readings.

 

The run-up was extreme. Per Bernstein, the stock had risen 587% year to date against a 52-week range of $22.28 to $254.48, with most of that gain coming after the August interim announcement.

 

Analysts rated the data positively. UBS called it solid data, TD Cowen called the 42% reduction compelling and within the exceptional range defined by medical experts, and Wells Fargo said the recurrence-free survival result exceeded investor expectations.

 

 

Setting out the order is a precondition for understanding the day's trading.

 

The data were scheduled for formal presentation on October 24 at the European Society for Medical Oncology meeting in Madrid, covering follow-up over the first two years after treatment. But during the October 22 US trading session, reports of a partial data leak reached the market, with the results reported to have appeared on an oncology website. The stock fell immediately and trading was briefly halted. Merck and Moderna then released the official results.

 

Price formation that day therefore had an unusual feature: the market first reacted to unverified leaked figures and then to the officially disclosed complete results, with both occurring inside one session. That explains why the intraday decline reached 25.2% while the closing decline was 17.57%, with a partial recovery in between.

 

The spread of the move was limited and concentrated. Merck fell 1.76% on the day, BioNTech, which shares the mRNA technology path, fell 1.77%, and Novavax fell 9.26%, while the S&P 500 fell 1.22% and the Nasdaq Composite fell 2.60%. The decline concentrated in Moderna itself rather than spreading through the sector or reflecting a systemic market drop.

 

That distribution is itself informative. Had the market read this data as invalidating mRNA individualised neoantigen therapy as a technology, Merck and BioNTech would have fallen much harder, whereas Merck, both the combination partner and the development collaborator, fell only about 1.76%. The implication is that what the market repriced was Moderna's valuation level rather than the viability of the technology.

 

 

Listing the design and results item by item prevents reading a statistical measure as a clinical promise.

 

 

The 42% figure needs its own explanation. The primary endpoint, recurrence-free survival, measures the time from randomisation to a first recurrence or death from any cause. A 42% risk reduction means the risk of experiencing recurrence or death fell 42% in the combination arm relative to the control arm over the observation period. It does not mean 42% of patients were cured, nor that a recurrence rate fell to 42%, nor an absolute difference in survival rates.

 

The choice of comparator matters just as much. The control here is not placebo but KEYTRUDA alone, itself an established adjuvant standard of care in this setting. The 42% therefore measures incremental benefit on top of an already effective treatment rather than benefit relative to no treatment, which makes the bar substantially higher than a placebo-controlled comparison.

 

That overall survival is not yet mature needs stating plainly. Recurrence-free survival is a surrogate endpoint, generally correlated with overall survival but not equivalent to it, and final assessments of adjuvant therapy by regulators and the medical community usually require overall survival data. The companies say they will continue evaluating overall survival and, per press reports, describe a favourable trend. For the therapy's mechanism and Phase 3 background, see our earlier explainer on Merck and Moderna's cancer vaccine.

 

 

This is the core of the article and the key to explaining the decline. Worth emphasising is that every expectation cited below comes from analysts' public statements rather than a benchmark set here.

 

The data itself drew fairly consistent positive assessments. UBS analyst Michael Yee called the recurrence-free survival result solid data. William Blair analyst Myles Minter called the trial data great. TD Cowen called the 42% recurrence reduction compelling and within the exceptional range defined by medical experts. Bernstein called it a strong Phase 3 result and meaningful validation of Moderna's individualised neoantigen platform. Wells Fargo went further, saying the recurrence-free survival result exceeded investor expectations and that concerns over the trial data may be overdone.

 

If so, the reason for the decline must lie outside the data, and analysts offered three explanations.

 

The first is that expectations had been pushed up in advance. UBS's Michael Yee stated explicitly that the pullback was an expected sell-the-news event and that expectations had been inflated partly by bullish commentary from the companies. That attribution matters, since the expectations were not purely market-generated.

 

The second is the base effect of the rally. Per Bernstein, the stock had risen 587% year to date, with other reports putting the gain above 500% or near 600% for the year, and most of it came after the August interim Phase 3 announcement. The 52-week range of $22.28 to $254.48 places the current price in the upper part of that band. From such a base, data that is positive without clearly exceeding expectations cannot support further gains.

 

The third is uncertainty about extending to other cancers. William Blair's Myles Minter noted investors may question whether the therapy works in other tumour types, and that such extension is necessary to justify the current valuation. Success in melanoma alone, in other words, is already in the price, and what the market prices next is the part not yet validated.

 

A pair of numbers illustrates the valuation disagreement. Bernstein rates Moderna Market Perform with a $45 price target against the $202.63 close. Trailing revenue stands at $2.23 billion, down 27.6% year over year, with trailing earnings of negative $8.01 per share, so the company remains loss-making, at a market capitalisation near $80.90 billion. Worth clarifying is that Wells Fargo's $165 target applies to Merck rather than Moderna, with an Overweight rating. Together these figures indicate the current price embeds expectations for future pipeline value rather than the earning power of the existing business.

 

One structural detail also deserves attention: the Phase 3 readings of 42% and 38% both fall below the 49% and 59% from five-year Phase 2b KEYNOTE-942 data. Per Merck's release, the Phase 2b recurrence-free survival hazard ratio was 0.51 with a 95% confidence interval of 0.294 to 0.887, and the distant metastasis-free survival hazard ratio was 0.411 with a 95% confidence interval of 0.200 to 0.843. Three qualifications attach to that comparison: the Phase 2b trial was far smaller than the Phase 3's 1,137 patients, and effect sizes in small trials typically run larger and regress in large ones; the Phase 2b figures are five-year data while the Phase 3 is an interim analysis covering the first two years; and the two trials differ in population and design. Treating the Phase 2 figures as a threshold the Phase 3 should have cleared is therefore not methodologically rigorous, yet it was the reference point the market could most readily use.

 

 

Setting the two events side by side clarifies what the market priced at each stage.

 

August brought interim Phase 3 results, showing reduced risk of recurrence and spread in high-risk melanoma patients, and the stock rose sharply. What was priced then was a directional question, namely whether the technology works in a large Phase 3 trial, and the answer was yes. Our review of that episode sits in our analysis of Moderna's August rally.

 

October 22 brought the detailed data, adding four things. First, the specific effect sizes of 42% on recurrence-free survival and 38% on distant metastasis-free survival. Second, explicit identification of the comparator as KEYTRUDA alone rather than placebo. Third, enrollment and randomisation at 1,137 patients split 2:1. Fourth, the status of overall survival as not yet mature.

 

What these four share is that they convert a qualitative conclusion into a comparable quantitative result. And once something is comparable, markets look for a reference point, with the nearest being the Phase 2 data. That is precisely how a directionally positive result and a shortfall in magnitude can coexist: August answered whether it works, October answered how well, and the latter left a gap relative to prior bullish commentary.

 

Seen this way, the decline is more accurately described as a correction to the rally and to expectations rather than a rejection of the therapy. Merck falling only 1.76% supports that reading.

 

 

Judgement from here rests on five areas.

 

First, the complete data presentation at the European Society for Medical Oncology meeting on October 24. That will disclose details not yet public, including hazard ratios and confidence intervals, performance across stage subgroups, and specific adverse event rates. Those details determine how the aggregate 42% distributes across different patient groups.

 

Second, continued overall survival follow-up. The companies say they will keep evaluating overall survival, and final assessment in the adjuvant setting generally requires that endpoint. Results may take several quarters or longer.

 

Third, regulatory filing progress. The companies say they plan to share the data with regulators and engage on filing submissions for intismeran in combination with KEYTRUDA, without providing a specific timetable or target markets.

 

Fourth, trials in other tumour types. Per William Blair's view, supporting the current valuation requires the therapy to work beyond melanoma, making readouts in other indications the key to whether the valuation holds.

 

Fifth, the company's financial fundamentals. Moderna reports on November 6, with trailing revenue of $2.23 billion down 27.6% year over year and trailing earnings of negative $8.01 per share. With no new product yet commercialised, the balance between cash burn and pipeline progress forms a separate line of observation.

 

 

 

For James Mitchell, what deserves recording about this decline is not its size but how cleanly it demonstrates that clinical merit and share price direction run on two independent systems of judgement. The trial met its primary endpoint and a key secondary endpoint with no new safety signals, analysts at five firms rated the data anywhere from solid to exceptional, Wells Fargo even judged the recurrence-free survival result as exceeding investor expectations, and the stock fell 17.57% that day. Both can hold simultaneously, because the former measures a medical conclusion while the latter measures the gap between data and the expectations already embedded in a price.

 

The shortfall has a quantifiable anchor. The Phase 3 readings of 42% and 38% both fall below the five-year Phase 2b figures of 49% and 59%, and those Phase 2 numbers appear in the company's own release. The comparison is not methodologically rigorous, since the Phase 2b sample was far smaller than the Phase 3's 1,137 patients with different follow-up duration, and effect sizes from small trials regressing in larger ones is an ordinary feature of clinical development. But when markets look for a reference point, they use the nearest and most available number rather than the most rigorous one. That is a general rule worth carrying into any event-driven situation.

 

More notable still is how expectations got elevated. UBS stated explicitly that expectations were inflated partly by bullish commentary from the companies. Once management has raised the bar itself, a result landing in the exceptional range may still fail to meet the elevated benchmark. For investors that suggests a practical standard: when assessing event risk, look not only at the data but at how emphatic management was before the announcement, because that determines where the passing mark sits.

 

Structurally, the current price has long priced in more than melanoma alone. Trailing revenue of $2.23 billion is down 27.6% year over year with trailing earnings of negative $8.01 per share against a market capitalisation near $80.90 billion, while Bernstein's target sits at $45 against a $202.63 close. Under that structure, success in a single indication cannot support the valuation, which depends on extension to other cancers that remains unvalidated. That is exactly the issue William Blair identified, and it is the real pricing variable for the next stage.

 

For investors, three judgements are more useful than the size of the drop. First, assess the trial conclusion separately from the share price reaction, and do not infer a problem with the therapy from a falling stock, since Merck's 1.76% decline already shows the market has not rejected the technology path. Second, watch overall survival, because recurrence-free survival is a surrogate endpoint while final valuation of adjuvant therapy requires overall survival support. Third, watch readouts in other tumour types, because that is what the current valuation implies while the melanoma result is largely priced already.

 

 

 

Because the data was positive without clearly exceeding elevated expectations, and the stock had already accumulated an enormous gain. Per Bernstein, it had risen 587% year to date, with most of that coming after the August interim Phase 3 results. UBS called the pullback an expected sell-the-news event and noted expectations had been inflated partly by bullish commentary from the companies. The Phase 3 readings of 42% and 38% also fell below the five-year Phase 2 figures of 49% and 59%, giving the market a shortfall to reference.

 

 

No. The companies state that Phase 3 INTerpath-001 met the primary endpoint of recurrence-free survival and the key secondary endpoint of distant metastasis-free survival at a pre-specified interim analysis, with statistically significant and clinically meaningful improvements over KEYTRUDA alone and a safety profile consistent with prior studies of the combination with no new safety signals. Overall survival data are not yet mature, and the trial continues to evaluate that endpoint.

 

 

It means the risk of experiencing recurrence or death from any cause fell 42% in the combination arm relative to the KEYTRUDA-alone control arm over the observation period. It is not a 42% cure rate, not 42% of patients benefiting, and not an absolute difference in survival rates. Worth noting alongside this is that the comparator is an established adjuvant standard of care rather than placebo, so the figure measures incremental benefit on top of effective treatment.

 

 

Because it was the most available reference point. Per Merck's release, five-year Phase 2b KEYNOTE-942 data showed a 49% reduction in recurrence-free survival risk at a hazard ratio of 0.51 and a 59% reduction in distant metastasis-free survival risk at a hazard ratio of 0.411, both above the Phase 3 readings. Three qualifications apply: the Phase 2b sample was far smaller than the Phase 3's 1,137 patients, and small-trial effect sizes typically run larger and regress in large trials; the Phase 2b figures are five-year data while the Phase 3 is a two-year interim analysis; and the trials differ in population and design.

 

 

They rated the data itself positively. UBS called it solid data, William Blair called the trial data great, TD Cowen called the 42% reduction compelling and within the exceptional range defined by medical experts, Bernstein called it a strong Phase 3 result and meaningful validation of the platform, and Wells Fargo said the recurrence-free survival result exceeded investor expectations while concerns may be overdone. The disagreement concentrates on valuation rather than efficacy, with Bernstein rating Moderna Market Perform at a $45 target.

 

 

Because what the market repriced was Moderna's valuation rather than the technology path. Merck fell 1.76% on the day, BioNTech fell 1.77% and Novavax fell 9.26%, while the S&P 500 fell 1.22% and the Nasdaq Composite fell 2.60%. Merck, both the combination partner and the development collaborator, fell roughly in line with the broad market, indicating the market did not read this data as invalidating mRNA individualised neoantigen therapy.

 

 

Five things. The complete data at the European Society for Medical Oncology meeting on October 24, including hazard ratios, confidence intervals and subgroup performance. Continued overall survival follow-up. Regulatory filing progress, where the companies say they will engage with regulators without giving a timetable. Readouts in other tumour types, which is what the current valuation implies. And the November 6 earnings report, with trailing revenue of $2.23 billion down 27.6% year over year and trailing earnings of negative $8.01 per share.

 

 

The information above is provided for general market information and analysis only and does not constitute investment advice, financial advice, legal advice, tax advice, medical advice or a recommendation to trade, nor does it constitute a professional assessment of any therapy's efficacy or safety. Prices of equities and other related financial assets can fluctuate sharply, and past performance, clinical trial results and analyst expectations do not guarantee future results. The trial data, risk reduction figures, analyst views, price targets and share prices cited here reflect publicly available information at the time of publication, different sources may use different bases, clinical data is governed by the companies' formal disclosures and the complete results presented at academic meetings, and regulatory approval and commercialisation arrangements remain uncertain. The risk reductions described are statistical measures of relative risk and do not represent cure rates, the proportion of patients benefiting, or absolute differences in survival rates; recurrence-free survival is a surrogate endpoint and overall survival data are not yet mature. Any decision concerning diagnosis or treatment should involve a qualified medical professional. Readers should conduct their own research before making any investment decision and judge against their own financial circumstances, investment objectives and risk tolerance, consulting a qualified professional where appropriate. The MEXC Crypto Pulse team accepts no liability for any direct or indirect loss arising from the use of this information.

 

 

James Mitchell specializes in technical analysis, market trends, and trading strategies for both Bitcoin and altcoins. Based in London, he has over 10 years of experience in financial markets. Before joining MEXC Learn, James worked as a senior analyst at a leading European investment firm, where he developed expertise in risk management and quantitative trading. His transition to cryptocurrency markets began in 2017, and he has since become recognized for his data-driven approach. He holds a Master's degree in Financial Economics from the London School of Economics. His analytical approach combines traditional technical analysis with on-chain metrics to provide readers with actionable insights.

 

Areas of Expertise: Technical Analysis, Market Trends and Cycles, Trading Strategies, Bitcoin and Altcoin Analysis, Risk Management.

 

 

 

Want the fastest access to MEXC's latest updates? Join our official Telegram group now!

MEXC Platform: Download App | Zero Fee Trading | Buy USDT Now

Join MEXC Community: X (Twitter) | Telegram | Discord

Get Insights: MEXC Learn | Terms of Service | MEXC Blog | MEXC News

Account Verification: Understand KYC | How to Complete KYC

External Content Platforms: Substack | Medium | Paragraph | LinkedIn | X(News)